Kidney transplantation
6 trials- 2024Felzartamab AMRAntibody-mediated rejectionIn 22 kidney-transplant recipients with chronic active antibody-mediated rejection, felzartamab resolved rejection morphology more often than placebo.
- 2018TRANSFORMmTOR inhibitorsIn 2,037 de-novo kidney-transplant recipients, everolimus with reduced calcineurin inhibitor was non-inferior for rejection, graft loss or death compared with mycophenolate with standard calcineurin inhibitor.
- 2017THINKERHCV-positive donorsIn 20 HCV-negative recipients of hepatitis-C-viraemic donor kidneys, antiviral therapy achieved a sustained virologic response in every patient.
- 2016BENEFITBelataceptIn 666 kidney-transplant recipients, belatacept improved 7-year patient and graft survival compared with ciclosporin.
- 2011ZEUSmTOR inhibitorsIn 300 kidney-transplant recipients, early conversion from ciclosporin to everolimus improved kidney function compared with continued ciclosporin.
- 2007ELITE-SymphonyImmunosuppressionIn 1,645 kidney-transplant recipients, low-dose tacrolimus with mycophenolate and steroids gave better graft function than the other immunosuppressive regimens.